Consolidated Financial Statements for the First Quarter Ended June 30, 2017 FY2018 (April 1, 2017 - March 31, 2018) [UNAUDITED]

July 27, 2017

Company name:	Takara Holdings Inc.
Stock exchange listings:	Tokyo Stock Exchange (1st section)
Code number:	2531
URL:	http://www.takara.co.jp/
Company representative:	Toshio Kakimoto, President
Contact:	Takuya Kakemi, General Manager of Investor Relations Dept.
	TEL:(075)241-5124
Quarterly statement filing dat	e (as planned): August 8, 2017

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.

2. Amounts are rounded down to the nearest million yen.

1. Results for the three months ended June 30, 2017 (April 1, 2017 - June 30, 2017) (1) Operating results

	Note: Percentages indicated changes from the previous fiscal year.			
	Three months ended June 30, 2017		Three months ended	
			June 30, 2016	
	(Millions of yon)	(0/,)	(Millions of	(%)
	(Millions of yen)	(%)	yen)	
Net sales	63,368	21.1	52,311	2.7
Operating income (loss)	2,074	27.3	1,630	151.0
Ordinary income (loss)	2,247	12.4	1,998	88.3
Net income (loss) attributable to owners of the parent	1,163	7.3	1,084	63.7
Net income (loss) per share (Yen)	5.78		5.39	
Fully diluted net income per share (Yen)	-		-	
Note: Comprehensive income	171	-	(3,242)	-

(2) Financial position

	As of June 30, 2017	As of March 31, 2017
	(Millions of yen)	(Millions of yen)
Total assets	280,443	274,368
Net assets	163,099	165,920
Equity ratio (%)	47.5	49.2
(Reference) Equity	133,088	135,043

2. Dividends

	Dividend per share (Yen)			
	Year ended March 31,	Year ending March 31,	Year ending March 31,	
	2017	2018	2018 (Forecast)	
First quarter end	-	-		
Second quarter end	-		-	
Third quarter end	-		-	
Year end	13.00		14.00	
Annual	13.00		14.00	

Note: Correction of dividend forecast from the most recent dividend forecast : No

3. Forecast for the year ending March 31, 2018 (April 1, 2017 - March 31, 2018)

• 0 / /	Note: Percentages indicated changes from the same period of the previous fiscal year.			
	Six months ending September 30, 2017		Year ending March 31, 2018	
	(Millions of yen)	(%)	(Millions of yen)	(%)
Net sales	125,000	16.3	268,000	14.4
Operating income (loss)	4,700	(9.7)	14,000	3.3
Ordinary income (loss)	4,700	(16.3)	14,400	0.4
Net income (loss) attributable to owners of the parent	2,400	(24.5)	8,500	0.2
Net income per share (Yen)	11.93		42.24	

Note: Correction of financial forecast from the most recent financial forecast : No

4. Others

(1) Material changes in subsidiaries during this period (Changes in scope of consolidations resulting from change is subsidiaries) : Yes Newly included: 2 (Name) WaferGen Bio-systems, Inc., Rubicon Genomics, Inc. Excluded: 1 (Name) Rubicon Genomics, Inc.

- (2) Applying of specific accounting of the consolidated quarterly financial statements : No
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
 - 1) Changes based on revisions of accounting standard : No
 - 2) Changes other than ones based on revisions of accounting standard : No
 - 3) Changes in accounting estimates : No

4) Restatement : No

- (4) Number of outstanding shares (common stock)
 - 1) Number of outstanding shares at year end (Treasury stocks are included)

- As of June 30, 2017 : 217,699,743
- As of March 31, 2017 : 217,699,743
- 2) Number of treasury stocks at year end
 - As of June 30, 2017 : 16,475,746
 - As of March 31, 2017 : 16,475,431
- 3) Average number of outstanding shares
 - Three months ended June 30, 2017 : 201,224,001
 - Three months ended June 30, 2016 : 201,224,342